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Abstract
Depression is a serious concern among patients and their family members 
undergoing treatment for acute and chronic illnesses. The quality of palliative care 
has great significance in improving the mental health of patients. The patient usually 
undergoes various stages of treatment before reaching the palliative care stage. 
Therefore, the tendency of denying treatment at later stages of illness increases. 
Depression could arise either early or at later stages of treatment. Most doctors feel 
restrained to prescribe antidepressants to the patient, as antidepressants could have 
a serious side effect on the physiology of the patient. Antidepressants only work 
for a smaller group of patients. A proper diagnostics and structured interview with 
extensive checks of reliability and viability could be used for assessment. Various fac-
tors like sociodemographic, gender, age, support health groups have a drastic effect 
on the mental health of the patient. Palliative care to the patients with social health 
support groups psychotherapy, relaxation meditation yoga, along with the appropri-
ate pharmacological approach, works wonders for some patients. Continued efforts 
should be made to treat and deal with depression in palliative care.
Keywords: depression, palliative care, acute, chronic illness, assessment, 
antidepressants
1. Introduction
Depression is thought to be one of the most serious and common mental disor-
ders that could arise in palliative care settings. The term depressed is widely misun-
derstood among a large section of people. Often depressed is misused by the word 
“feeling sad”. Many physical symptoms like fatigue, weight loss, sleep cycle, weak-
ness, lack of interest are common in advanced illness. There should be proper moni-
toring of symptoms in depression. A survey was done by Lauren Rayner and team 
[1] that determined the pervasiveness of depression in patients receiving palliative 
care, after the initial assessment by clinicals, nurses 300 patients were interviewed. 
According to the survey, 58 patients met the criteria for MDD (major depressive 
disorder) while 109 met the criteria for any depressive disorder. Males were more 
prone to MDD. Depression could not be only identified by somatic symptoms, 
but a proper psychological assessment and support are also needed. A study done 
by Franca Warmenhoven and team suggested that [2] many physicians failed to 
distinguish between the normal and abnormal sadness, patients receiving pallia-
tive care, the therapeutic and diagnostic processes for depression is a continuous 
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and overlapping process. There is high non-specificity in diagnostic methods for 
depression in palliative care settings. The occurrence of depression also depends 
upon the past life of the patients and their relationship with their family members. 
A study conducted by Moira o Connor, Kate white RN and team upon patients with 
cancer in Western Australia and new south wales [3], has shown that depression is 
more prevalent in patients with a family history of anxiety. Many patients bat-
tling life-threatening illnesses have gone through a lot of pain, trauma, diagnostic 
measures by the time they approach palliative care. Each of the phases they have 
gone through has a psychological impact on the patient. Depending upon the diag-
nostic criteria used the rates of depression could range from 3–69% [4]. Gender, 
age, demographics widely influence the personality and mental status of patients. 
Participants diagnosed with mental disorders were significantly younger than the 
other participants and have a smaller social network. Women are significantly likely 
to be more depressed than men (P = 0.082) [5]. Patients receiving palliative care 
with moderate to severe depression could be benefited from an intense narrative 
intervention as the score reduced on PHQ-9 [patient health questionnaire, it is a 
multiple-choice questionnaire that is used for screening for depression]. Healthcare 
workers who understand the background of patients thoroughly with practitioners 
could deliver the intervention. Intervention is a partially structured narrative that 
is performed by experienced scientists with research trainers who had background 
knowledge of patients with advanced illness [6]. Patients are more prone to depres-
sion in advanced stages of illness (Figure 1). Helping patients with support groups 
in the initial stages of disease could prove effective. Taking care of patients suffer-
ing from idiopathic pulmonary fibrosis is very challenging because at that time no 
medication could prove its efficacy that could improve the quality of patient’s life, 
but many therapies could reduce symptoms in patients. However, a placebo effect 
could have improved the outcome, when introduced to the support groups and 
palliative care have increased the quality of life [7]. A comorbid condition for the 
patient in palliative care could be very challenging to treat. A study suggested that 
psychotherapy when given to patients with advanced and serious illness in palliative 
care can reduce symptoms of depression and tends to improve the quality of life [8]. 
Cognitive-behavioral therapy helps the patients to accept the condition and treat 
emotional distress, intervention narrated by health professionals also has significant 
effects [8]. Detection of depression in palliative care screening could be an effective 
way as it excludes the non-depressed patients from the depressed ones, but one 
disadvantage is that it could not detect the degree to which a diagnostic criterion is 
applied to the patient. Comprehensive clinical evaluation should not be substituted 
by screening but supplement it. Mostly the detected cases rarely take into account 
the duration of symptoms. The ability to detect and treat depressive symptoms 
should be an initial priority to treat depression in palliative care [9, 10]. To achieve 
quality palliative care, an acceptable or good amount of psychological care is a must. 
Figure 1. 
Factors responsible for depression in patients.
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Most patients face a stigma from seeking help from medical professionals, thus it 
should be dealt with and solved. Members of the medical and research team should 
arm themselves with interactive communication skills. Unconsciously or unknow-
ingly the healthcare workers should be very vigilant not to portray hopelessness or 
any negative thought in respect to the disease diagnosis or treatment to the patient. 
They should be compassionate and empathetic towards the patient. In the advanced 
stages of the disease, the intensity and frequency of physical symptoms can vary. 
Screening for mood disorders and depression should be done in patients expressing 
the significantly high intensity of physical symptoms to provide treatment to the 
condition [11]. Lack of support system from friends and family at the time of pallia-
tive care is certainly a risk factor for non-remission. A strong correlation was found 
between remission of depression and improvement of physical symptoms [12]. An 
additional amount of psychological care could benefit depressed patients in pallia-
tive care with low support groups for their treatment [12]. Psychological therapies 
including cognitive behavior therapy showed some positive results in the treatment 
procedure. Some interventions like antidepressants and psychostimulants remain 
challenging, requiring a wide level of clinical trials. Pharma logical approach when 
combined with psychotherapy, support group therapy, an aromatherapy massage 
could be proven very effective in treating depression [13]. A study performed in 
cancer patients to detect depression states that no method has been completely 
accurate for definitive screening. Detailed tests combined with simple questions 
could be considered as a method. Work carried out in future generation should be 
beyond screening for psychopathy alone, there is a wide variety of psychological 
distress that also require medical help [14].
2. Assessment and diagnosis
The first step is the assessment and is one of the most important and crucial 
steps in the diagnosis of depression. This step could itself be very challenging in the 
environment. In a study, a structured interview was constructed for assessing the 
symptoms of patients in the advanced cancer stage receiving palliative care. Visual 
analogue scales (VAS) were also completed by the participants along with the 
interview. Impressive interrater reliability was shown by interview items (interclass 
correlations were > 0.9). Structured interview for symptoms and concerns was 
found to be sensitive between each participant of the subgroup. Thus, a structured 
interview method of assessment could be proven reliable and valid way in deter-
mining depression during palliative care [15]. To treat a disease, the first step is to 
identify it. Undetected depression in patients receiving palliative care could lead to 
severe consequences. Often physicians find it difficult to distinguish between 
sadness and depression in patients with advanced illness at the end of their life so 
there should be a different diagnostic mechanism for determining depression in 
terminally ill patients. Correlation between subscale of depression and HADS 
(hospital anxiety and depression scale) of the 25 patients that were admitted to a 
hospice correlated with 100 mm linear Visual analogue scale (VAS). VAS thus was 
thought to be an effective screening tool for patients who were suffering from 
depression in advanced disease [16]. Hospital anxiety and depression scale (HADS) 
could be used in yielding numerical scores and is quite acceptable to the patients. 
The person who deals with this scale should have proper knowledge and time to deal 
with psychological and emotional stress generated by its use. There comes a time 
when patients tend to have consistent high HADS scores, a proper review should be 
maintained in that situation. Earlier detection could be made possible by regular 
screening from the referral time and thus could be followed by treatment protocols 
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[17]. Psychological distress comes in many ways and forms. Its proper assessment 
makes it a big task. Psychiatric questionnaires when routinely assessed by the 
clinical staff could produce proper results. Awareness could be raised in non-
psychiatric staff by educational programs, screening for the disease could be most 
effective when it coupled with informative and educational seminars in the pres-
ence of responsible psychiatric input. The attention of psychologists and research-
ers is often attracted by unidimensional scales like distress thermometers because 
they are easy to use, but there is always a question on their validity in complex 
psychological constructs. The scale with a length of 6–30 items is multidimensional 
scales that focuses on a wide variety of distress like somatic, behavioral. The large 
size of the questionnaire poses one disadvantage. Identifying the causes of depres-
sion, distressing symptoms, mood swings that co-exist with other illnesses in the 
patient could be detected through the HADS anxiety subscale. To improve the 
clinical issue, screening for psychological issues should be the priority. To gain as 
many benefits as possible from screening it should be accompanied by validation of 
treatment. There is a minute difference between assessment and screening for a 
disorder that is assessment is a more complex process that involves various steps like 
identification of the problem, a good therapeutic relationship followed by manage-
ment strategies, whereas screening involves only identification of the psychological 
distress that eventually leads to assessment in the identified patients [18]. Patients 
suffering from advanced stages of cancer often face mood disorders and various 
psychiatric problems which are often underdiagnosed or overlapped with the 
symptoms of the disease. This may be led to severe difficulties and the patient could 
lead to poor quality of life. A comparison was bought in the screening procedure 
between Edmonton Symptom Assessment System (ESAS) for depression with 
Hospital Anxiety and Depression Scale (HADS). The study suggested that a sample 
of 216 patients were analyzed using ESAS and the score for depression was found 
to be 2(0–10) and 6(0–16) using HADS. The sensitivity using ESAS was found out to  
be 77% and 83% and specificity was found out to be 55% and 47% for moderate to 
severe depression. The cut-off point that was analyzed using ESAS for the screening 
of depression in palliative care was 2 out of 10 [19]. Interviewing for psychiatric 
illness in the palliative care setting is very important. There was a comparison 
between formal psychiatric interview compared with two-item screening interview 
which determined the specificity and sensitivity of two item screening interview 
was the main objective in the study to identify the depressed patients in palliative 
care study. The sensitivity and specificity of the two-item questionnaire were found 
out to be 90.7% and 67.7%. The false-positive and false-negative results were 32.3% 
and 9.3%. The study concluded that the two-question screening tool has high 
sensitivity and low false-negative results. There was also an easy detection and the 
patients tend to respond positively to the two-item questionnaire who previously 
had some experience of depression in the earlier stage than the patients with no 
prior history of depression [20]. One in four palliative care patients tends to show 
symptoms of depression, so the screening tool therefore must be very accurate. A 
comparison was drawn out between three screening tools. The initial was the 
verbally rating mood on the scale of 0–10, responding to the question that was 
asked to the patients “Are you Depressed?” in either yes or no format, and last was 
the completion of the Edinburg depression scale. Using DSM IV criteria, a semi-
structured interview was also performed. When determined the sensitivity and 
specificity of the “yes” answer it was found to be 55% and 74%. The sensitivity  
and specificity of verbally rating mood on the scale were found to be 80% and 43% 
and at last, the Edinburg depression scale was found to be highly accurate with the 
sensitivity of 70% and specificity of 80%. In comparison to these three scales, the 
Edinburg depression scale was found to be highly reliable in detecting depression in 
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patients in palliative care [21]. In medical oncology and palliative care settings 
patients are prone to depression. The rapid screening for depression could be 
validated by BCD (Brief Case find for Depression). A comparison was drawn out to 
carry the validation of BCD in a palliative care setting with Primary Care Evaluation 
of Medical Disorders (PRIME -MD), HADS and beck depression inventory (BDI). 
Validity was constructed by comparing depressed patients and non-depressed 
patients relating to symptoms, pain, performance status by using these methods the 
prevalence of depression was found to be 34%, 12%, 19% and 14% respectively of 
BCD, PRIME MD, BDI and HADS. BCD was found to be much sensitive than other 
instruments as it detected a higher rate of depression as compared to other meth-
ods. BCD when compared to PRIME MD could recognize both major and minor 
depression whereas PRIME MD could be used for detection for major depression 
among patients. The validity of BCD could also be proved by patients having a high 
BDI score, HADS depression score with probable depression on BCD compared to 
those without probable depression. A comparison was also drawn between 
depressed patients according to BCD and non-depressed patients significantly 
showed scores on the higher side on PRIME MD. The administration of BCD is not 
very complicated, could be a part of a routine clinical interview. The results could 
be obtained immediately. Depression and anxiety are often thought to be the 
same, distinction was obtained between these two by using BCD that supports its 
 discriminatory validity. Thus, BCD could be introduced in standard clinical 
 practices [22].
3. Diagnostic challenges
Patients with severely ill conditions receiving palliative care are prone to depres-
sion and other psychiatric illnesses but assessing these psychiatric conditions could 
be very challenging by the medical staff. Multiple somatic symptoms are expressed 
in the patients with advanced cancer which could overlap with symptoms of depres-
sion, thus depression assessment could be very challenging. The study found out the 
occurrence of depression was significantly related to poor performance status and 
more pain. One could not exclude somatic symptoms in the assessment of depres-
sion which could have a direct or indirect relation with it. Comorbid depression 
characterization was increasing pain, poorer physical condition than expected nor-
mally [23]. There should be no omission of somatic symptoms when as they remain 
influential in the diagnosis of depression. All somatic symptoms were present in any 
depressive disorder (ADD) like insomnia or sleeping too much, poor appetite, lack 
of concentration, etc., whereas major depressive disorder includes both somatic and 
non-somatic symptoms. Defining depression with HADS score the symptoms were 
psychologically followed up by somatic symptoms. Thus, in a palliative care setting 
symptoms like poor appetite, feeling tired overpowered symptoms like feeling bad 
or speaking slowly. There should be proper symptom diagnosis to determine the 
broad or narrow concept of depression [24] Many clinical find these steps challeng-
ing as to differentiate between the symptoms (Figure 2). Mood disorders symptoms 
can be the effect of physiological impairment in the body. Pancreatic cancer is 
highly malignant, and it is very hard to treat. Patients are often feared for it because 
of its deadly reputation. Patients that develop psychological conditions like mood 
disorders, depression is likely the outcome of disruptive physiological conditions 
of the pancreas like impaired secretion of hormones, digestive enzymes or neu-
rotransmitters. Thus, here the reason for psychological symptoms was impaired 
physiological processes of the patients [25]. Depression prevalent among cancer 
patients could range from 3.8–58%. 25% patients suffer from depression who have 
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been hospitalized with a significant level of physical impairment [26]. Barriers in 
assessment could form if there arises confusion about depression with some differ-
ent sources of sadness among cancer patients. The consequence of depression could 
lead to suicidal or self-harm tendencies if not assessed properly. It is unclear that 
patients having a comorbid condition like having cancer with depression could be 
worse than patients only having depression without underlying disease. There is an 
uncertainty in identifying symptoms of depression in patients with severe diseases 
because the symptoms tend to overlap with the disease. The cases of depression are 
often missed. Physicians and nurses were capable of identifying only half of the 
cases and half of the cases were left undetected [27, 28]. A study was conducted 
that determined the accuracy of physicians to detect depressive symptoms among 
patients. A survey was performed on 1,109 subjects who were treated by 12 oncolo-
gists by 25 ambulatory oncology clinics that were affiliated with community cancer 
care Indiana [29]. Subjects had to complete ZSDS (Zung Self-Rating Depression 
Scale) and physicians rated their patients based on depressive symptoms, pain, 
anxiety. To detect depression physicians, tend to rate their patients based on how 
the patient endorses on the ZSDS scale (Figure 3). The rating of the physician 
was also influenced by the medical correlation of the patient. The patient’s mood 
symptoms like sadness, hopelessness also affected the rating. Physicians tend to be 
affected by symptoms like crying mood, depressive mood, but this could not be 
labeled as the reliable indicator of depression [29]. In the UK, a study was done to 
assess the ability of 143 doctors in 34 cancer centers and hospitals [31]. It was found 
out that the misclassification of psychiatric morbidity in 34.7% of 797 patients 
and wrong assessment was made. There was a lack of proper communication skills 
between doctors and the patients. There should be a need in the improvement of 
skills during the consultation [31]. Many patients from rural background who are 
not economically capable of affording a psychiatrist are often left undetected. In 
physically ill patients, the diagnosis of depression is often complicated because of 
pervasive somatic symptoms that could be or could not be due to primary disease. 
In confounding somatic symptoms many options have been proposed. Symptoms 
that are directly caused by medical conditions are excluded according to DSM IV. 
The distinction between the symptoms practically could be very challenging. For 
Figure 2. 
Differentiating between symptoms of depressions.
Figure 3. 
Zung self rating depression scale (ZSDS standard scale) [30].
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the diagnosis of major depressive disorder, 5 out of 9 symptoms should be present 
when all the symptoms were excluded. This is highly standardized that could only 
identify severely depressed patients [32, 33]. When the false-negative results are 
greater, there is a failure to treat depression, or false-positive results the risk of 
initiating unnecessary therapy. Cassem suggests that clinicals should include on 
the side of caution the somatic symptoms in diagnosing medically ill patients [34]. 
However, when the approach suggested by Cassem is used there could be a possibil-
ity of prevalence of an exaggerated number of patients with the depressive disorder 
[15, 34].
4. Treatment and therapies
When depression is identified in patients with terminal illness requires various 
measures to treat it. Treatment procedures could include pharmacological treat-
ment, psychological treatment or the combination of both of these. A study was 
conducted to prove the efficacy of antidepressants in patients with depression 
in palliative care. It was found out the administration of antidepressants in these 
patients was found to be more effective than the placebo effect, and it was more 
apparent within 4–5 weeks and increased with its continuous use [35]. Patients 
showing depressive symptoms or depressed anxiety mixed symptoms were daily 
given oral doses of ketamine hydrochloride. In this 28-day trial, there was found to 
be a significant improvement in both depressive and anxiety symptoms in patients, 
the improvement was significant and gradual for 28 days with some rare side effects 
like diarrhea, insomnia, trouble sitting [36]. There is a slight misconception that the 
psychotherapeutic approach is not beneficial in severely depressed patients but in 
a study done by Driessen, et al., it was found that psycho-therapeutic approaches 
could be beneficial in both mild and severe depression [37].
5. Psychotherapy
Depressive symptoms that diminish with psychological interventions can 
also be provided by medical caregivers apart from the specialist in psychological 
oncology. When the relation of health care workers with the patients is perceived 
as supportive then the patients with cancer tend to show less traumatic stress. 
Patients with leukemia significantly show stress symptoms which are associated 
with physical symptoms, psychological intervention could prevent traumatic stress 
in the patients. A study of breast cancer patients identified that women who don’t 
have emotional support from family and friends have difficulty in interacting with 
nurses and physicians [38, 39]. For both undergraduate and postgraduate medical 
training, there is deterioration in clinical empathy [40].
Several types of psychological therapies are being performed depending upon 
the severity of depressive symptoms (Figure 4) stage of the disease, the interest of 
the patient and motivation to participate in psychological therapy. Cancer patients 
who were diagnosed with mild to moderate depression could be benefitted from 
cognitive behavioral therapy, methods of relaxation, approaches to problem-solving 
[40–42]. Supportive expressive therapy could be beneficial for the patients who 
have more advanced disease that targets the fear related with death and existential 
concerns. Many psychotherapies have been developed like meaning-centred group 
therapy which is beneficial spiritual and emotional wellbeing [43], dignity therapy 
which empowers meaning to life [44], mindfulness-based meditation therapy, 




Administration of antidepressants in physically healthy patients has shown 
improvement in treating depression, but when it comes to treating physically ill 
patients there has been a serious doubt in using it. Tricyclic antidepressants (TCA) 
and selective serotonin reuptake inhibitors (SSRI) are two classes of antidepressants 
that showed effective results than the placebo effect. But patients stopped taking 
them after 6–8 weeks of treatment because they experienced serious side effects like 
sexual dysfunction and dry mouth [47]. There is an inhibition of cytochrome P450 
by SSRI drug–drug interaction. Citalopram is well tolerated as it has the fewest drug 
interaction compared to fluvoxamine which is a potent inhibitor of CYP1A2 and 
CYP2C19. The assessment of SSRI drug combination should be administered on an 
individual basis [48]. Drugs such as quetiapine and olanzapine are some antipsy-
chotic medications that have been proposed for symptom palliation because they 
are thought to improve insomnia, appetite changes, nausea related to chemotherapy 
with some additional effects on depression, but rather than cancer population its 
efficacy is derived from general psychiatric [49]. Fatigue and symptoms of depres-
sion are very common in terminally ill older patients with advanced illnesses. 
Administration of methylphenidate showed possible effectiveness towards depres-
sive symptoms and fatigue because of its rapid onset of action [50]. Patients that 
develop depression in palliative care were restricted and not allowed to use psy-
chostimulants according to European guidelines [51]. Physicians prescribing drugs 
should be well aware of their toxicity and interactions with other drugs. When 
antidepressants were administered to the patient’s suicidal tendencies increased 
mostly between young adults and adolescents [52]. It is important to study drug 
interaction because patients with cancer when administered antidepressants can 
alter the pharmacokinetics of the other drugs that were prescribed to the patient for 
its illness. For example, women who received tamoxifen for the treatment of breast 
cancer when administered with antidepressants can significantly decrease the sur-
vival chances. Paroxetine which is a potent irreversible inhibitor of CYP2D6 which 
is an antidepressant when administered with tamoxifen increases the risk of death 
in breast cancer patients [53]. Antidepressants to the patient should be provided fol-
lowing its symptoms of depression and physical illness. In a study done by Mehmet 
et al., it was found that when low doses of mirtazapine were administered for the 
treatment of depression in cancer patients, it was significantly safe until 24 weeks 
period of time, which reduced depressive symptoms [54].
7. Age, demographics gender
Depression is common in patients with serious illness in palliative care. Age fac-
tor could also contribute to its prevalence. A study was conducted in determining 
the prevalence of depression in heart failure patients [55]. In the total of patients, it 
Figure 4. 
Therapies performed to treat depression.
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was found out 48% of the patients were depressed [55]. Younger patients tend to be 
more depressed when compared to non-depressed patients. The age group between 
19 and 29 had a 5% depression rate, 30–44 years had a 7.5% prevalence of depres-
sion and those over 65 years had the least depression rate that is 1.4% (Figure 5). 
When compared between men and women (64%) of women are likely to be more 
depressed than men (44%) [55].
8. Social support and support groups
Support groups for the patients suffering from depression in palliative care 
could be beneficial as it is associated with the gradual improvement of depressive 
symptoms and helps in improving the patient’s emotional stress and quality of 
life of the patient. Cancer patients when participated in these support groups had 
a positive impact [56]. Patients with ostomy when participated in ostomy sup-
port group functioned at much more advanced levels than they were in any other 
previous support group. They experience a willingness to live and tried making new 
friends [57]. The efficiency of support groups increases when there is additional 
social support provided by friends and family members. A study done on breast 
cancer patients analyzed that how women cope with stress and anxiety [58]. It was 
found out that women who received social support from family showed an effective 
way of coping with stress. For effective stress management, it was determined that 
social support was very necessary [58]. Apart from family and friends nurses also 
play a crucial role in providing social support to the patients. In the medical staff 
nurses are the ones that are closest to the patient when they need anything. The con-
nection between patients and healthcare is built by nurses themselves, so they need 
to understand the whole social support system and the nurses should be trained in 
providing counseling to the patients who are unable to get social support. In a study 
done on breast cancer patients, there was found to be a direct relationship between 
psychiatric morbidity and social [59]. For patients suffering from different types 
of cancer, one year after diagnosis for psychological disorder it was found out that 
31.8% of the patients were diagnosed with depression who had low social support 
scores [59, 60]. A study conducted on different types of cancer, breast cancer, other 
cancer and mixed cancer by Bina Nausheen and team, results collectively suggested 
that there is a relationship between cancer progression and social support is strong 
for breast cancer [61].
Depression is treatable in palliative care patients if one identifies it at the right 
time. Delayed diagnosis will always lead to delayed treatment which in order will 
worsen the situation. In the assessment procedure VAS (Visual analogue scale) 
is very effective for screening depression that correlated well with HADS [16]. 
Another sensitive diagnostic method is BCD (Brief Case find for Depression) 
which is very simple to administer which could detect both major and minor 
depression. PRIME MD (Primary Care Evaluation of Medical Disorders) has a 
Figure 5. 
Prevalence of depression in different age groups [55].
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certain limitation that it could identify only major depressive disorders [22]. For 
the assessment to be smooth and functioning, there should be well-equipped 
hospitals with improvised mechanisms and techniques and well-trained staff. 
When patients were openly asked about feeling depressed the responses recorded 
from most of the patients were less sensitive and showed false results because the 
patients tend to hide their illness because of them being stigmatized. The stigma 
of depression should be eradicated as it hampers the testing problem. To eradicate 
this stigmatization one must preach to everyone in the family and hospital staff, 
should organize some seminars and conduct workshops. Many of the medical staff 
and even doctors treating patients are not well aware of depression as a psycho-
logical illness. For the patients to be comfortable with the doctors and staff, there 
should be good interpersonal communication skills between both doctors and the 
patients, which could be established by a non-judgemental and emphatic behavior 
of doctors towards patients [31]. The mental and emotional support from friends 
and family to the patient at the time of illness could also help the patient to recover 
more likely than those who do not have it. In the hospital where nurses play a vital 
role and act as a bridge between doctors and patients, they need to be well trained 
and highly professional. Untrained staff and nurses in the hospital could be a major 
reason for prolonged and untreated depression in the patients. Once the depression 
is assessed, treatment methods could be both psychological and pharmacological. 
The major limitation of pharmacological drugs is it has certain side effects in some 
patients apart from treating depression [35, 47, 49, 51]. Patients who experience side 
effects from antidepressants or psychostimulants should be treated in combination 
with psychotherapy, yoga and meditation are also effective in the treatment process 
which helps the patient to achieve peace of mind.
9. Conclusion
Depression is very common in patients with terminal or life-threatening illnesses 
in a palliative care setting. It is therefore important to diagnose it at a right time. 
Diagnosing it at a right time will result in effective treatment and could improve the 
symptoms. There could be many hurdles for the physician to diagnose it because of 
the overlapping with physical symptoms of the illness. The medical staff should be 
trained to give counseling to the patients. Many patients tend to resist their treat-
ment because of a lack of social support from family and friends. Psychotherapy 
which includes various therapies like cognitive behavior therapy was found to be 
effective in the treatment procedure. Antidepressants when given to patients with 
depression but with no illness could be very effective but when given to patients 
with some advanced illness had severe side effects. Doctors must resist the use of 
drugs that tend to interact with other drugs because it could hamper the treat-
ment of the patients. Social support from family and friends plays a crucial role in 
combatting depression as it increases the quality of life and gives meaning to live a 
life, lack of a support system could also be a reason for depression. When it comes to 
gender, women are the ones who tend to be more depressed than men. Young ado-
lescents and adults when compared to people on the older side are more depressed. 
There is a lack of hope, suicidal tendencies in the patient with depression. Thus, 
depression could be a serious challenge in the palliative care settings due to various 
reasons and we need to deal with it in a more precise way.
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